These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25374673)

  • 1. Future therapy of portal hypertension in liver cirrhosis - a guess.
    Sauerbruch T; Trebicka J
    F1000Prime Rep; 2014; 6():95. PubMed ID: 25374673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology and a Rational Basis of Therapy.
    Gracia-Sancho J; Maeso-Díaz R; Bosch J
    Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Methotrexate, liver and rheumatoid arthritis in tropical areas].
    Diouf ML; Diallo S; Mbengue M; Moreira-Diop T
    Sante; 2001; 11(3):195-200. PubMed ID: 11641084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing portal hypertension in patients with liver cirrhosis.
    Sauerbruch T; Schierwagen R; Trebicka J
    F1000Res; 2018; 7():. PubMed ID: 29780579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.
    Piscaglia F; Salvatore V; Mulazzani L; Cantisani V; Schiavone C
    Ultraschall Med; 2016 Feb; 37(1):1-5. PubMed ID: 26871407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients.
    Ratti L; Pozzi M; Bosch J
    Dig Liver Dis; 2005 Nov; 37(11):886-93. PubMed ID: 16172033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrahepatic upregulation of MRTF-A signaling contributes to increased hepatic vascular resistance in cirrhotic rats with portal hypertension.
    Zheng L; Qin J; Sun L; Gui L; Zhang C; Huang Y; Deng W; Huang A; Sun D; Luo M
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):303-310. PubMed ID: 28043789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Viral liver cirrhosis: natural course, pathogenesis and clinical implications of the complications].
    Gentilini P; Laffi G; La Villa G; Casini-Raggi V; Romanelli RG; Buzzelli G; Mazzanti R; Marra F; Pinzani M; Zignego AL
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():23S-29S. PubMed ID: 9004817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
    Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
    J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of non-selective beta blockers on portal hypertension and hepatic elasticity in hepatitis C virus-related liver cirrhosis.
    Zaghloul SG; Wahab EA; Seleem WM; Hanafy AS; Gomaa AF; Lakouz K; Amin AI
    Drug Discov Ther; 2019; 13(2):108-113. PubMed ID: 31080201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type C chronic hepatitis associated with thrombocytopenia in two patients.
    Yabu K; Kiyosawa K; Ako S; Usuda S; Yoshizawa K; Tanaka E; Sodeyama T; Furuta S
    J Gastroenterol Hepatol; 1994; 9(1):99-104. PubMed ID: 8155875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-cirrhotic portal hypertension in HIV mono-infected patients.
    Jackson BD; Doyle JS; Hoy JF; Roberts SK; Colman J; Hellard ME; Sasadeusz JJ; Iser DM
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1512-9. PubMed ID: 22497527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Specific development and course of portal hypertension complication in patients with hepatic cirrhosis of HBV and HCV etiology].
    Nazyrov FG; Deviatov AV; Babadzhanov AKh; Sultanov SA
    Vestn Khir Im I I Grek; 2011; 170(1):22-9. PubMed ID: 21506350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications of cirrhosis. I. Portal hypertension.
    Bosch J; García-Pagán JC
    J Hepatol; 2000; 32(1 Suppl):141-56. PubMed ID: 10728801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
    Thabut D; Shah V
    J Hepatol; 2010 Nov; 53(5):976-80. PubMed ID: 20800926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long course and prognostic factors of virus-induced cirrhosis of the liver.
    Gentilini P; Laffi G; La Villa G; Romanelli RG; Buzzelli G; Casini-Raggi V; Melani L; Mazzanti R; Riccardi D; Pinzani M; Zignego AL
    Am J Gastroenterol; 1997 Jan; 92(1):66-72. PubMed ID: 8995940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat.
    Hsieh YH; Huang HC; Chang CC; Chuang CL; Lee FY; Hsu SJ; Huang YH; Hou MC; Lee SD
    J Pharmacol Exp Ther; 2018 Nov; 367(2):260-266. PubMed ID: 30194095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. China's efforts to shed its title of "Leader in liver disease".
    Li X; Xu WF
    Drug Discov Ther; 2007 Oct; 1(2):84-5. PubMed ID: 22504391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New cellular and molecular targets for the treatment of portal hypertension.
    Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
    Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C? .
    Ladero JM; Cárdenas MC; Ortega L; González-Pino A; Cuenca F; Morales C; Lee-Brunner A
    Ann Hepatol; 2012; 11(5):648-51. PubMed ID: 22947524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.